• PR4 BACK PAIN IN GERMANY- ARE THERE DIFFERENCES CONCERNING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS TREATED ACCORDINGTO GUIDELINES, GUIDELINE INDEPENDENT AND PATIENT SELF-TREATMENT?

    Nov 1, 2007, 00:00

  • PND28 COMPARISON OF FOUR PREFERENCE-BASED SF-36/SF-I2 ALGORITHMS TO EVALUATE THE COST-EFFECTIVENESS OF TREATMENT FOR PRIMARY INSOMNIA WITH ESZOPICLONE

    Nov 1, 2007, 00:00

  • PDB70 EVALUATING CLINICAL AND PATIENT-REPORTED OUTCOMES (PROS) FOR PATIENTS WITH DIABETES PARTICIPATING IN A COMPREHENSIVE DISEASE MANAGEMENT PROGRAM

    Nov 1, 2007, 00:00

  • PDB60 ASSOCIATION OF INADEQUATE METABOLIC CONTROL AND CO-MORBIDITIES AND HEALTH RESOURCE UTILIZATION IN PATIENTS WITH DIABETES MELLITUS IN A SPANISH POPULATION

    Nov 1, 2007, 00:00

  • PND24 TRENDS IN ANTI-ALZHEIMER'S MEDICATION UTILIZATION AND ASSOCIATED PATIENT CHARACTERISTICS IN SPAIN- RESULTS FROM A LARGE MULTI-CENTER ALZHEIMERMONITOR INITIATIVE

    Nov 1, 2007, 00:00

  • PIH18 VALIDITY OF A CHILD-FRIENDLY EQ-5D AS A GENERIC HEALTH OUTCOME INSTRUMENT IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS IN GERMANY

    Nov 1, 2007, 00:00

  • PHP21 IMPACT OF DISCONTINUITY IN HEALTH INSURANCE ON RESOURCE UTILIZATION

    Nov 1, 2007, 00:00

  • PHM20 VALUE OF TRANSFUSION-FREE LIVING IN MDS- RESULTS OF HEALTH UTILITY INTERVIEWS WITH MDS PATIENTS

    Nov 1, 2007, 00:00

  • PMH27 COST-EFFECTIVENESS OF DULOXETINE VS. VENLAFAXINE XRAND SSRIS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN PRIMARY AND SECONDARY CARE IN SPAIN

    Nov 1, 2007, 00:00

  • ED3 DIFFERENCES IN HEALTH RELATED RESOURCE USE IN THE 6 MONTHS PRIOR TO AND AFTER INSULIN INITIATION IN PATIENTS WITHTYPE 2 DIABETES IN GERMANY AND UNITED KINGDOM- DATA FROMTHE INSTIGATE STUDY

    Nov 1, 2007, 00:00

  • PCV64 CLINICAL AND ECONOMIC IMPACT OF DRUG-ELUTING STENT AND BARE METAL STENT IN HONG KONG-A SINGLE CETRE “REAL WORLD” EXPERIENCE- AN INTERIM ANALYSIS

    Nov 1, 2007, 00:00

  • PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL

    Nov 1, 2007, 00:00

  • PAA14 PHYSICIANS EDUCATIONAL EFFORTS- A TOOL FOR IMPROVING MANAGEMENT OF ASTHMA IN THE COMMUNITY

    Nov 1, 2007, 00:00

  • PUK22 AN OBSERVATIONAL STUDY ON THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH A NEUROGENIC OVERACTIVE BLADDER TREATED WITH TOLTERODINE ER

    Nov 1, 2007, 00:00

  • PG115 PERSISTENCE WITH INFLIXIMAB THERAPY REDUCES CROHN'S DISEASE RELATED MEDICAL COSTS

    Nov 1, 2007, 00:00

  • PIH16 INTERNET SURVEY- A NEW AND VALID TOOL TO ESTIMATE THE BURDEN OF OTITIS IN CHILDREN 5 YEARS OLD

    Nov 1, 2007, 00:00

  • PCN2 RETROSPECTIVE CHART REVIEW OFTHE MANAGEMENT OF HAND-FOOT SYNDROME IN THE TREATMENT OF COLORECTAL CANCER

    Nov 1, 2007, 00:00

  • PGI25 DEVELOPMENT AND VALIDATION OF PATIENT REPORTED OUTCOMES MEASUREMENT SCALES FOR CROHN'S DISEASE- THE INFLAMMATORY BOWEL DISEASE IMPACT AND SYMPTOM SCALES (IBDIMSYS)

    Nov 1, 2007, 00:00

  • PND1 BUDGETARY ANALYSIS OF AMBULATORY CARE STRATEGY FOR PATIENTS WITH TRANSIENT ISCHEMIC ACCIDENT (TIA)

    Nov 1, 2007, 00:00

  • Patient-Reported Outcomes- Instrument Development and Selection Issues

    Nov 1, 2007, 00:00

  • PAA17 PHYSICIAN ADHERENCE TO NATIONAL ASTHMA PRESCRIBING GUIDELINES- EVIDENCE FROM U.S. OUTPATIENT VISITS

    Nov 1, 2007, 00:00

  • PIN45 HOWTO IMPROVE THE EXTERNAL VALIDITY AND EXTEND THE EXPIRATION DATE OF ECONOMIC EVALUATIONS

    Nov 1, 2007, 00:00

  • PSM1 COST-EFFECTIVENESS ANALYSIS OF CHAMPIX® (VARENICLINE) IN SMOKING CESSATION TREATMENT IN SPAIN

    Nov 1, 2007, 00:00

  • PIN25 A COST-EFFECTIVENESS STUDY OF A UNIVERSAL VACCINATION PROGRAM WITH THE 7-VALENT PNEUMOCOCCAL VACCINE (PCV-7) IN SWEDEN

    Nov 1, 2007, 00:00

  • PMH11 RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA- 12 MONTH PRELIMINARY RESULTS FROM E-STAR PROJECT IN CZECH REPUBLIC AND SLOVAKIA

    Nov 1, 2007, 00:00

  • PCV46 ECONOMIC EVALUATION OF 80 MG ATORVASTATIN COMPARED TO 20-40 MG SIMVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES

    Nov 1, 2007, 00:00

  • PCV84 WHAT FACTORS AFFECT COMPLIANCE OF HYPERTENSIVE PATIENTS WITH THEIRTREATMENT? A QUALITATIVE STUDY

    Nov 1, 2007, 00:00

  • PMH50 A BELGIAN PILOT PROJECT TESTING THE FEASIBILITY AND ACCEPTABILITY OF SHORT MESSAGE SERVICE (SMS)TEXT MESSAGING TO PATIENTS TREATED WITH QUETIAPINE

    Nov 1, 2007, 00:00

  • PMS2 PATIENT-REPORTED-OUTCOMES (PRO) AS A DRIVEN OF DIRECT HEALTH COSTS IN SUBJECTS WITH FIBROMYALGIA A LONGITUDINAL RETROSPECTIVE PRIMARY CARE SETTINGS (PCS) CLAIM DATABASE ANALYSIS

    Nov 1, 2007, 00:00

  • PR7 PATIENT'S PREFERENCES FOR OSTEOPOROSIS DRUG TREATMENT- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2007, 00:00

  • PG128 IMPACT OF CERTOLIZUMAB PEGOL ON QUALITY-ADJUSTED LIFE-YEARS IN TWO INDUCTION AND MAINTENANCE TRIALS IN PATIENTS WITH ACTIVE CROHN'S DISEASE

    Nov 1, 2007, 00:00

  • PSM6 REAL WORLD USAGE PATTERNS OF OVER-THE-COUNTER NICOTINE PATCHES

    Nov 1, 2007, 00:00

  • SU3 NINEYEAR FOLLOW UP OF BIRMINGHAM HIP RESURFACING IN CONTEXT OF SURVIVAL AND COMPLICATIONS

    Nov 1, 2007, 00:00

  • Productivity Costs Associated with Cardiometabolic Risk Factor Clusters in the United States

    Nov 1, 2007, 00:00

  • PMH5 THE COMPARATIVE EFFICACY OF SECOND-GENERATION ANTIDEPRESSANTS FORTHE ACUTE-PHASE TREATMENT OF MAJOR DEPRESSIVE DISORDER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2007, 00:00

  • PCV92 ATTITUDES AND BELIEFS OF PATIENTS WITH HIGH CARDIOVASCULAR RISK, ABOUT HYPERCHOLESTEROLEMIA AND ITS TREATMENT IN SPAIN. THE PRACTICE STUDY

    Nov 1, 2007, 00:00

  • PCV83 ADHERENCE WITH ANTIHYPERTENSIVE DRUG TREATMENT- EVIDENCE FROM PRIMARY CARE PRACTICE IN ITALY

    Nov 1, 2007, 00:00

  • PND18 HEALTH AND NON-HEALTH RESOURCES UTILIZATION AND DERIVED COSTS OF TREATING UNDER ROUTINE MEDICAL PRACTICE REFRACTORY PAIN ASSOCIATED TO TRIGEMINAL NEURALGIA IN PRIMARY CARE SETTING (PCS)- A 12-WEEKS LONGITUDINAL POST-HOC ANALYSIS

    Nov 1, 2007, 00:00

  • PCV47 COST-EFFECTIVENESS OF ENDOVASCULAR REPAIR (EVAR) COMPARED WITH OPEN SURGERY REPAIR (OSR) FOR THE TREATMENT OF ABDOMINAL AORTIC ANEURYSM (AAA) IN ITALY

    Nov 1, 2007, 00:00

  • PIN3 AWORKSITE INFLUENZA VACCINATION PROGRAM IN RUSSIAA COST-BENEFIT ANALYSIS

    Nov 1, 2007, 00:00

  • PHM9 COST OF ILLNESS OF DIFFUSE LARGE B-CELL LYMPHOMA IN RUSSIA

    Nov 1, 2007, 00:00

  • PAR12 FINANCIAL CONSEQUENCES OFTHERAPEUTIC STRATEGIES IN OSTEOARTHRITIS TREATMENT IN CZECH REPUBLIC

    Nov 1, 2007, 00:00

  • PUK19 TREATMENT OUTCOMES AND MEDICAL CARE OF PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO) RECEIVING BOTULINUM TOXIN A (BOTOX®) THERAPY

    Nov 1, 2007, 00:00

  • PG112 THE DUEC (DIGITAL ULCERS ECONOMIC COST) STUDY- ECONOMIC BURDEN OF DIGITAL ULCERS IN ITALIAN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS

    Nov 1, 2007, 00:00

  • PDB34 LONG-TERM COST-EFFECTIVENESS ANALYSIS OF A MODERN INSULIN IN PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES IN THE GERMAN SETTING; DATA FROMTHE PREDICTIVE STUDY

    Nov 1, 2007, 00:00

  • PND6 COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE PRESENCE OF LONG-TERM CLINICAL EVIDENCE

    Nov 1, 2007, 00:00

  • PMH6 ATTAINING REMISSION OF DEPRESSIVE SYMPTOMS IN THE PIVOTAL RANDOMISED CLINICAL TRIALS OF DULOXETINE IN MAJOR DEPRESSION. WHICH ARE THE MOST EFFICACIOUS DOSES?

    Nov 1, 2007, 00:00

  • PHP1 ECONOMIC ANALYSIS OF THE BAVARIAN BLOOD AND PLASMA MARKET- LESSONS FOR THE FUTURE

    Nov 1, 2007, 00:00

  • PMC24 THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE (SIAQ®)- DEVELOPMENT AND CONTENT VALIDATION

    Nov 1, 2007, 00:00

  • PND3 BUDGET IMPACT OF DOPAMINE AGONISTS IN POLAND

    Nov 1, 2007, 00:00

  • PHM19 USING THE EQ-5DTO MONITOR HEALTH-RELATED QUALITY OF LIFE OVERTIME IN THE CATALAN HEALTH INTERVIEW SURVEY

    Nov 1, 2007, 00:00

  • PHP13 THE COST OF WASTED MEDICINES IN PORTUGAL

    Nov 1, 2007, 00:00

  • PDB52 FACTORS ASSOCIATED WITH THE CHOICE OF A GLITAZONES OR SULFONYLUREA AS ADD ON TO ONGOING METFORMIN MONOTHERAPY

    Nov 1, 2007, 00:00

  • PDB79 THE DIABETES MEDICATION SATISFACTION TOOL (DMSAT)- DEVELOPMENT AND VALIDATION OF A NEW PATIENT-CENTERED OUTCOMES INSTRUMENT FOR CLINICIANS

    Nov 1, 2007, 00:00

  • MC4 COMPARISON OFTHREE INSTRUMENTS ASSESSING THE QUALITY OF ECONOMIC EVALUATIONS

    Nov 1, 2007, 00:00

  • PCN3 ECONOMIC IMPACT OF SECOND- ANDTHIRD-LINE ERLOTINIB TREATMENT OF NON SMALL-CELL LUNG CANCER-A FRENCH OBSERVATIONAL STUDY

    Nov 1, 2007, 00:00

  • PSK10 QUANTITATIVE ASSESSMENT OF PATIENT-DEFINED BENEFIT IN DERMATOLOGY

    Nov 1, 2007, 00:00

  • PAR28 GEOGRAPHICAL VARIATION OF PHARMACOLOGICAL PRESCRIPTION WITH BAYESIAN HIERARCHICAL MODELS

    Nov 1, 2007, 00:00

  • PCV60 VARIATION OF OUTLIER PAYMENTS AMONG HOSPITALS

    Nov 1, 2007, 00:00

  • PUK1O- DIRECT COST OF URINARY INCONTINENCE OF ICELANDIC WOMEN, 16 YEARS AND OLDER IN THEYEAR 2001

    Nov 1, 2007, 00:00

  • PCN56 INTERNATIONAL INCIDENCE OF MEN WITH UNCERTAIN INDICATION FOR RADICAL PROSTATECTOMY- AN EVIDENCE-BASED ANALYSIS

    Nov 1, 2007, 00:00

  • CASE4 DEVELOPMENT ANDVALIDATION OF A CAREGIVER GASTROENTERORITIS KNOWLEDGE QUESTIONAIRE

    Nov 1, 2007, 00:00

  • PMH56 A REVIEW OF INSTRUMENTS USED TO ASSESS THE IMPACT OF ALCOHOLISM ON QUALITY OF LIFE

    Nov 1, 2007, 00:00

  • PIN35 MODELING THE LONG TERM CONSEQUENCES OF SUPPRESSING VIRAL REPLICATION IN CHRONIC HEPATITIS B-A COST-EFFECTIVENESS ANALYSIS OF ENTECAVIR IN SPAIN

    Nov 1, 2007, 00:00

  • PPN9 PERCEPTION OF BREAKTHROUGH PAIN IN PATIENTS WITH CHRONIC PAINFUL CONDITIONS

    Nov 1, 2007, 00:00

  • PCV65 LIKELIHOOD OF INITIATING ANTILIPIDEMICS BY PATIENT SEX, RACE/ETHNICITY, AGE, AND COMORBIDITY- LARGE-SCALE ANALYSIS OF FLORIDA MEDICAID-ENROLLED ADULTS WITH NEWLY DIAGNOSED DYSLIPIDEMIA

    Nov 1, 2007, 00:00

  • PAA12 EXTENT OF UNCONTROLLED DISEASE AND ASSOCIATED MEDICAL COSTS IN SEVERE ASTHMA IN THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PAR23 COST-UTILITY OF ABATACEPT, A NEW BIOLOGIC TREATMENT FOR PATIENTS WITH RHEUMATOID ARTHRITIS WHO FAILED ANTI-TNF THERAPY

    Nov 1, 2007, 00:00

  • PEY13 TIME TO DISCONTINUATION OF GLAUCOMA MEDICINES PRESCRIBED SUBSEQUENT TO INITIAL THERAPY

    Nov 1, 2007, 00:00

  • PND7 AN ANALYTICAL MODEL TO PREDICT THE COST-EFFECTIVENESS OF LONG-TERM ESZOPICLONE FOR THE TREATMENT OF PRIMARY INSOMNIA

    Nov 1, 2007, 00:00

  • PGI21 THE VALUE OF INFORMATION OF SCREENING FOR HEREDITARY HEMOCHROMATOSIS

    Nov 1, 2007, 00:00

  • PCV69 SIMPLE SENSITIVITY ANALYSIS TO ASSESS THE IMPACT OF ROUNDING OF BLOOD PRESSURE MEASUREMENTS ON ESTIMATES OF CONTROL RATES

    Nov 1, 2007, 00:00

  • PCV41 COSTS AND LENGTH OF STAY IN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE

    Nov 1, 2007, 00:00

  • PCV50 COSTS OF MAJOR BLEEDS IN ACUTE CORONARY SYNDROME PATIENTS

    Nov 1, 2007, 00:00

  • PMH35 SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND- A COST ANALYSIS

    Nov 1, 2007, 00:00

  • PMC5 USE OF A DIAGNOSIS-BASED RISK ADJUSTMENT MODEL TO ESTIMATE COSTS OF INDIGENT CARE IN A COMMUNITY AT MEDICAID REIMBURSEMENT RATES

    Nov 1, 2007, 00:00

  • PAR18 HIDDEN COST OF RHEUMATOID ARTHRITIS- ESTIMATING COST OF COMORBID CARDIOVASCULAR DISEASE AND DEPRESSION AMONG RHEUMATOID ARTHRITIS PATIENTS

    Nov 1, 2007, 00:00

  • PHP24 TRENDS OF PATIENT COSTS PER CASE IN ALBERTA, CANADA

    Nov 1, 2007, 00:00

  • PND12 MODELING THE CLINICAL AND ECONOMIC CONSEQUENCES OF TREATING RELAPSING FORM OF MULTIPLE SCLEROSIS WITH SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON-BETA-IA

    Nov 1, 2007, 00:00

  • PMH40 IMPACT OF AN INSPECTOR'S STAMP APPROVAL POLICY INTO THE ATYPICAL ANTIPSYCHOTIC MARKET IN ANDALUSIA (SPAIN)

    Nov 1, 2007, 00:00

  • PCV1 AN OBSERVATIONAL STUDY OF THE EFFECTIVENESS OF ROSUVASTATIN IN PATIENTS WITH DIABETES IN GENERAL PRACTICE ACROSS THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PCV29 THE COST-EFFECTIVENESS ANALYSIS OF CORONARY ARTERY DISEASE DIAGNOSTIC PARAMETERS IN A CLINICAL LABORATORY SETTING

    Nov 1, 2007, 00:00

  • POS2 CORRELATION BETWEEN PREDICTORS AND SUBSEQUENT SURGICAL MANAGEMENT FOLLOWING INTERNAL FIXATION OF FEMORAL NECK FRACTURES

    Nov 1, 2007, 00:00

  • PMH28 A PHARMACOECONOMIC EVALUATION OF ESCITALOPRAM VS. PAROXETINE IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER IN NORWAY

    Nov 1, 2007, 00:00

  • PIN27 THE COST-EFFECTIVENESS OF UNIVERSAL INFLUENZA VACCINATION FOR 50-64 YEAR-OLDS IN AUSTRALIA

    Nov 1, 2007, 00:00

  • PMH24 THE COST EFFECTIVENESS OF PALIPERIDONE EXTENDED-RELEASE OROS IN SWEDEN, FINLAND, DENMARK AND NORWAY

    Nov 1, 2007, 00:00

  • PEY5 COST-EFFECTIVENESS MODELING OF LUCENTIS VERSUS USUAL CARE IN AGE RELATED MACULAR DEGENERESCENCE

    Nov 1, 2007, 00:00

  • PMH37 PAIN IN DEPRESSION AND PRODUCTIVITY LOSS—(RESULTS FROM UK SUBSET OF THE EUROPEAN FACTORS INFLUENCING DEPRESSION ENDPOINTS RESEARCH (FINDER) STUDY)

    Nov 1, 2007, 00:00

  • MD4 COST-EFFECTIVENESS OF BONE DENSITOMETRY SCREENING COMBINED WITH ALENDRONATE THERAPY FOR THOSE WHO HAVE OSTEOPOROSIS

    Nov 1, 2007, 00:00

  • PND30 ANALYSIS OF TRIPTAN REFILLING BEHAVIOR AMONG FEMALE MIGRAINEURS

    Nov 1, 2007, 00:00

  • PDB18 THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH ROSIGLITAZONE-AN ECONOMIC EVALUATION PROJECTING RESULTS FROM A CLINICAL STUDY INTOTHE FUTURE USING AVALID AND RELIABLE ECONOMIC MODEL FROM ATHIRD PARTY PAYER PERSPECTIVE IN THE USA

    Nov 1, 2007, 00:00

  • PCV17 METABOLIC CONTROL AND COSTS OF PATIENTS WITH HIGH CARDIOVASCULAR RISK. A CROSS SECTIONAL ASSESSMENT OF A HEALTH MANAGEMENT ORGANIZATION DATABASE

    Nov 1, 2007, 00:00

  • POB3 A PROBABILISTIC BAYESIAN MARKOV MODEL IN WINBUGS FOR THE ECONOMIC EVALUATION OF THE TREATMENT WITH ORLISTAT OF ITALIAN OBESE PATIENTS

    Nov 1, 2007, 00:00

  • PCN67 ESTIMATION OF IMPORTANT DIFFERENCES IN EQ-5DVAS SCORES IN CANCER

    Nov 1, 2007, 00:00

  • PCV77 RESPONSE-SHIFT IN HEART DISEASE- COMPARING INDIVIDUALIZED VS. DISEASE-SPECIFIC HRQL INSTRUMENTS

    Nov 1, 2007, 00:00

  • PDB62 LONG-TERM CLINICAL OUTCOMES OF INSULIN DETEMIR VERSUS NPH FORTYPE I DIABETES PATIENTS IN SPAIN

    Nov 1, 2007, 00:00

  • DB1 IMPACT OF ROSIGLITAZONETHERAPY ONTHE LIPID PROFILE AND LIPID-LOWERINGTREATMENT IN TYPE 2 DIABETES PATIENTS

    Nov 1, 2007, 00:00

  • PCV57 UTILISATION OF DRUGS FOR TREATMENT OF CARDIOVASCULAR DISEASE WITHIN SLOVAKIA

    Nov 1, 2007, 00:00

  • PRS9 ECONOMIC EFFECTS AND SUSTAINABILITY OF A STRUCTURED CARE PROGRAMME FOR COPD PATIENTS

    Nov 1, 2007, 00:00

  • PMH59 LINGUISTIC VALIDATION OF THE HADS FOR USE IN INTERNATIONAL STUDIES

    Nov 1, 2007, 00:00

  • PPN4 HEALTH, NON-HEALTH RESOURCES UTILIZATION AND COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE IN SPAIN

    Nov 1, 2007, 00:00

  • PIN34 PREDICTORS OF COSTS FOR SKIN AND SKIN STRUCTURE INFECTIONS DUE TO ST/IPH/LOCOCCUS/IUREUS USING A MANAGED-CARE PERSPECTIVE

    Nov 1, 2007, 00:00

  • PHP18 HEALTH CARE DECISION-MAKERS'ATTITUDE ON HEALTH ECONOMICS RESEARCH

    Nov 1, 2007, 00:00

  • POB5 QUANTIFYING THE QUALITY OF ECONOMIC EVALUATIONS OF OBESITY INTERVENTIONS- A CRITICAL APPRAISAL OF THE LITERATURE

    Nov 1, 2007, 00:00

  • PHP19 IMMUNIZATION PROGRAM IN PARAGUAY- SOCIAL AND BEHAVIORAL DETERMINANTS AND ORGANIZATIONAL IMPACT

    Nov 1, 2007, 00:00

  • PMH34 A PHARMACOECONOMIC OUTCOMES ANALYSIS COMPARING RISPERIDONE LONG-ACTING INJECTION AND CONVENTIONAL DEPOT ANTIPSYCHOTICS

    Nov 1, 2007, 00:00

  • PND11 COMPARATIVE ANALYSIS OF MULTIPLE SCLEROSIS COST-EFFECTIVENESS MODELS- FOCUS ON THE UNITED STATES MANAGED CARE PERSPECTIVE

    Nov 1, 2007, 00:00

  • CASE1 UTILIZING AN INTERNET-BASED SYSTEM TO DELIVER A PHARMACY-CENTRIC ALERT AND INTERVENTION IN A MANAGED CARE SETTING

    Nov 1, 2007, 00:00

  • PIH6 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH TRAUMATIC INJURY AMONG PEDIATRICS IN THE UNITED STATES

    Nov 1, 2007, 00:00

  • PCN31 COST MINIMIZATION ANALYSIS OF CAPECITABINE+CISPLATIN IV VS 5-FLUORURACIL IV+CISPLATIN IVAS FIRST LINE THERAPY FORADVANCED GASTRIC CANCER FROM THE BRAZILIAN SOCIETAL PERSPECTIVE

    Nov 1, 2007, 00:00

  • PND20 COST-UTILITY ANALYSIS EVALUATING THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST-HERPETIC NEURALGIA IN GERMANY

    Nov 1, 2007, 00:00

  • PAR3 COST-BENEFIT OF RITUXIMAB FOR RHEUMATOID ARTHRITIS PATIENTS IN ARGENTINA

    Nov 1, 2007, 00:00

  • CV7 COMPARISON OFTHE COST-EFFECTIVENESS OF SEROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN RELATION TO PATIENT CORONARY ARTERY DISEASE STATUS

    Nov 1, 2007, 00:00

  • PND37 A REVIEW OF PATIENT-REPORTED OUTCOMES THAT COMPLEMENT ASSESSMENTS OF SEIZURE REDUCTION IN ADULT EPILEPSY DRUG TRIALS

    Nov 1, 2007, 00:00

  • PEY4 COST-EFFECTIVENESS ANALYSIS OF FIXED COMBINATION THERAPIES GANFORT, DUOTRAV AND XALACOM IN EUROPEAN COUNTRIES

    Nov 1, 2007, 00:00

  • PIH11 ROLE OF BLACK BOX WARNINGS AND FORMULARY MANAGEMENT

    Nov 1, 2007, 00:00

  • PCV39 COST UTILITY ANALYSIS OF CLOPIDOGREL IN ADDITION TO STANDARD CARE FOR ST-ELEVATED MYOCARDIAL INFARCTION-THE UK PERSPECTIVE

    Nov 1, 2007, 00:00

  • PAA18 USING CLAIMS DATA TO MODELTHE BUDGETARY IMPACT OF A NEW TREATMENT FOR RHINITIS

    Nov 1, 2007, 00:00

  • PAA9 RISK-ADJUSTED COSTS AND OUTCOMES FOR MILD PERSISTENT ASTHMA PATIENTS ON ALTERNATIVE CONTROLLER THERAPIES

    Nov 1, 2007, 00:00

  • PCV56 STATIN PRESCRIPTION PATTERNS IN A LOCAL HEALTH UNIT- A FIVE-YEAR-ANALYSIS

    Nov 1, 2007, 00:00

  • PMH13 IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)- 18 MONTH INTERIM RESULTS FROM BELGIAN PATIENTS ENROLLED IN THE ELECTRONIC SCHIZOPHRENIA TREATMENT A ...

    Nov 1, 2007, 00:00

  • PCN5 THE IMPORTANCE OF A RATIONAL USE OF HIGH COSTING CHEMOTHERAPY AGENTS IN A CHEMOTHERAPY UNIT OF A TERTIARY CANCER HOSPITAL IN BRAZIL

    Nov 1, 2007, 00:00

  • PHP33 RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS

    Nov 1, 2007, 00:00

  • PHM6 COST-EFFECTIVENESS OF INTRAVENOUS IRON VERSUS ORAL IRON IN ANEMIA TREATMENT IN ONCOLOGY, CHRONIC KIDNEY DISEASE AND POST-PARTUM PATIENTS

    Nov 1, 2007, 00:00

  • PIN38 AFFORDABILITYOFANTIMALARIAL DRUGS IN BENIN CITY, NIGERIA

    Nov 1, 2007, 00:00

  • PCN40 HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT- AN ECONOMIC MODEL OF THE IMPACT ON GERMAN HEALTH CARE COSTS

    Nov 1, 2007, 00:00

  • CV4 BENEFIT/RISK OF IRBESARTAN/HYDROCHLOROTHIAZIDE AS FIRST-LINE TREATMENT OF SEVERE HYPERTENSION

    Nov 1, 2007, 00:00

  • PHP39 PROVISION OF ESSENTIAL MEDICINES AND PHYSICIANS QUALITY PERCEPTION OF ARGENTINA HEALTH CARE SERVICES

    Nov 1, 2007, 00:00

  • PHP6 NETWORKING TOWARDS FUNCTIONAL POLICY-TOOLS- CAN CONDITIONAL REIMBURSEMENT OF DRUGS LEAD TO EFFICIENT AND EFFECTIVE DRUG USE?

    Nov 1, 2007, 00:00

  • PDB50 UTILIZING OF CLAIMS DATABASES FOR IMPROVEMENT OF PRESCRIPTION HABITS FOR DIABETES MELLITUSTYPE 2

    Nov 1, 2007, 00:00

  • PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL AND PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN

    Nov 1, 2007, 00:00

  • MD3 CHANGES IN BODYWEIGHT AND ASSOCIATED DOSING REQUIREMENTS FOR RHEUMATOID ARTHRITIS PATIENTS RECEIVING INFLIXIMAB—RESULTS FROM ANALYSIS OFTHE BRITISH SOCETY FOR RHEUMATOLOGY'S BIOLOGICS REGISTER (BSRBR)

    Nov 1, 2007, 00:00

  • PMH22 A PHARMACOECONOMIC ANALYSIS OF COMPLIANCE GAINS ON ANTIPSYCHOTIC MEDICATIONS

    Nov 1, 2007, 00:00

  • PCN50 COST SHIFTING EFFECT IN DRG BASED ANTI-CANCER THERAPIES IN HUNGARY

    Nov 1, 2007, 00:00

  • PAA6 COST EFFECTIVENESS OF BREATH-OPERATED INHALERS IN UNITED KINGDOM PRIMARY CARE

    Nov 1, 2007, 00:00

  • PPN6 HEALTH, NON-HEALTH RESOURCES UTILIZATION AND COSTS OF TREATING REFRACTORY PERIPHERAL NEUROPATHIC PAIN (NEP) IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE IN SPAIN

    Nov 1, 2007, 00:00

  • PMH46 THE SENSITIVITYTO CHANGE OF THE HAMILTON (HAMD) AND THE MONTGOMERY-ASBERG (MADRS) SCALES AS OUTCOME MEASURES IN ANTIDEPRESSANT TRIALS

    Nov 1, 2007, 00:00

  • MD2 ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS ATREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS IN THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PEN1 TIME-AND-MOTION EVALUATION OF DIFFERENT GROWTH HORMONE FORMULATIONS

    Nov 1, 2007, 00:00

  • PCN20 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • CN3 EFFECTIVENESS OF EPOETIN ALPHA VERSUS DARBEPOETIN IN CHEMOTHERAPY-INDUCED ANAEMIA INTHE GERMAN SETTING

    Nov 1, 2007, 00:00

  • POS9 COMPARATIVE ANALYSIS OF THE COST-EFFECTIVENESS OF TERIPARATIDE [RHPTH(l-34)] VERSUS RHPTH(l-84)

    Nov 1, 2007, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2007, 00:00

  • PDB32 EVALUATING THE LONG-TERM CLINICAL AND ECONOMIC IMPLICATIONS OF CONVERTING TYPE 2 DIABETES PATIENTS TO INSULIN DETEMIR (±ORAL HYPOGLYCEMIC AGENTS) FROM INSULIN GLARGINE BASED REGIMENS IN GERMANY; DATA FROMTHE PREDICTIVE STUDY

    Nov 1, 2007, 00:00

  • PMH29 SWITCHING FROM BRANDED TO GENERIC RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA- AN ESTIMATION OF POTENTIAL ECONOMIC CONSEQUENCES IN THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PHM16 PHARMACOKINETIC-PHARMACODYNAMIC-PHARMACOECONOMIC (P3) MODELING TO INFORM PHARMACOGENOMIC TRIAL DESIGN AND RISK MANAGEMENT

    Nov 1, 2007, 00:00

  • PDB75 THE TRANSLATION AND LINGUISTIC VALIDATION OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ) FOR USE IN EASTERN EUROPE

    Nov 1, 2007, 00:00

  • PND32 ALZHEIMER'S DISEASE PROGRESSION HEALTHY-YEAR EQUIVALENTS- STATED RISK-BENEFIT TRADE-OFF PREFERENCES

    Nov 1, 2007, 00:00

  • PCV78 MONITORING AND ASSESSING ADHERENCE TO STATINS THERAPY IN REAL PRACTICE USING ADMINISTRATIVE DATABASES

    Nov 1, 2007, 00:00

  • PG14 ECONOMIC EVALUATION COMPARING LANSOPRAZOLE AND ESOMEPRAZOLE IN THE ACUTE MANAGEMENT OF UNINVESTIGATED DYSPEPSIA

    Nov 1, 2007, 00:00

  • PMH16 ASSOCIATION BETWEEN ATYPICAL ANTIPSYCHOTIC USE AND TREATMENT-EMERGENT DIABETES, HYPERLIPIDEMIA, AND OBESITY

    Nov 1, 2007, 00:00

  • PDB30 EVALUATING THE COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR THE TREATMENT OFTYPE 2 DIABETES IN A SPANISH SETTING

    Nov 1, 2007, 00:00

  • PMC14 ORDINAL OR CARDINAL? THE VAS STRIKES BACK

    Nov 1, 2007, 00:00

  • PIN37 COST-UTILITY OF ALFAPEGINTERFERON-2A (40 KD) IN CO-INFECTED PATIENTS IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL

    Nov 1, 2007, 00:00

  • PND36 FIT OF THE MIGRAINE PREVENTION ASSESSMENT CLINICAL TOOL (M-PACT)WITH QUALITATIVE DEVELOPMENT GUIDELINES FOR PATIENT REPORTED OUTCOMES

    Nov 1, 2007, 00:00

  • PG18 COST-EFFECTIVENESS OF ESOMEPRAZOLE IN THE TREATMENT OF ADOLESCENT PATIENTS WITH REFLUX OESOPHAGITIS

    Nov 1, 2007, 00:00

  • PDB12 ROSIGLITAZONE IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES- IMPLEMENTATION OF BUDGET IMPACT ANALYSIS SOFTWARE

    Nov 1, 2007, 00:00

  • PSK12 PATIENT REPORTED OUTCOMES IN PSORIASIS

    Nov 1, 2007, 00:00

  • PND35 MEASURING THE IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE- A SYSTEMATIC REVIEW

    Nov 1, 2007, 00:00

  • PSM5 USE OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ)ANDTHE ENVIRONMENTAL TOBACCO SMOKE QUESTIONNAIRE (ETS-Q) IN AN INTERNATIONAL STUDY

    Nov 1, 2007, 00:00

  • PMC33 GUIDELINES FOR ENSURING DEGREES OF VALIDITY IN HEALTH ECONOMIC MODELS

    Nov 1, 2007, 00:00

  • PIN23 COST-EFFECTIVENESS ANALYSIS OF THE IMPLEMENTATION OF A QUADRIVALENT (6,1 1, 16,18 TYPES) HUMAN PAPILLOMAVIRUS VACCINE TO THE EXISTING BELGIAN CERVICAL CANCER SCREENING PROGRAMME

    Nov 1, 2007, 00:00

  • PRS5 REDUCTION IN TOTAL TREATMENT COSTS THROUGH IMPROVED PHARMACEUTICAL TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES

    Nov 1, 2007, 00:00

  • PCN57 BASIC ATTITUDE TO USE OF GENERIC ANTI-CANCER DRUGS FOR BREAST CANCER TREATMENT IN JAPAN

    Nov 1, 2007, 00:00

  • PHP14 GENERIC PRESCRIPTION MEDICINES PRICE VARIATION AMONG COMMUNITY PHARMACIES, PUBLIC HOSPITAL PHARMACIES AND DISPENSING DOCTORS IN ZIMBABWE

    Nov 1, 2007, 00:00

  • PG17 COST-EFFECTIVENESS ANALYSIS OF TREATING CHORNIC HEPATITITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN EARLY BEFORE DISEASE PROGRESSES TO MORE ADVANCED STAGE

    Nov 1, 2007, 00:00

  • PMH26 USING THE NET-BENEFIT REGRESSION APPROACH TO COMPARE THE COST-EFFECTIVENESS OF HALOPERIDOL, OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA

    Nov 1, 2007, 00:00

  • PND29 RETROSPECTIVE MEASUREMENT OF UNCODED DISEASE OUTCOMES IN A CLAIMS DATABASE

    Nov 1, 2007, 00:00

  • PHP35 PROFILE OF PHYSICIANS' PRESCRIPTION IN GREECE

    Nov 1, 2007, 00:00

  • PDB69 DETERMINANTS OF STOPPING TREATMENT WITH ORAL ANTIDIABETIC DRUGS IN DAILY CLINICAL PRACTICE

    Nov 1, 2007, 00:00

  • PND21 INSOMNIA AND SLEEP LOSS- WORKPLACE PRODUCTIVITY LOSS AND ASSOCIATED COSTS

    Nov 1, 2007, 00:00

  • PHP22 THE GREEK PHARMACEUTICAL EXPENDITURE DATA- EFFECTS OF THE NATIONAL ACCOUNTS' REVISION

    Nov 1, 2007, 00:00

  • PDB74 EFFECTS OF AN INTENSIFIED THERAPY WITH INSULIN GLARGINEAND INSULINE GLULISINE ON PATIENT REPORTED OUTCOMES IN DIABETES MELLITUS

    Nov 1, 2007, 00:00

  • PR3 PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS

    Nov 1, 2007, 00:00

  • PCV11 ASSOCIATION AND CONTROL OF MAIN CARDIOVASCULAR RISK FACTORS IN A SPANISH POPULATION SECTOR; A CROSS-SECTIONAL STUDY

    Nov 1, 2007, 00:00

  • POS10 COST-OF-ILLNESS STUDY OF HIP FRACTURE AMONG KOREAN ELDERLY WOMEN- INCIDENCE-BASED APPROACH

    Nov 1, 2007, 00:00

  • PMH38 INFLUENCE OF BEHAVIOURAL SYMPTOMS ON RESOURCES USE IN DEMENTIA

    Nov 1, 2007, 00:00

  • PIN32 OUTCOMES AND COSTS OF HOSPITAL-ACQUIRED PNEUMONIA ASSOCIATED WITH PSEUDOMONAS OR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN A SAMPLE OF BELGIAN HOSPITALS

    Nov 1, 2007, 00:00

  • PHP8 THE CHALLENGE OF A LEGITIMATE BUDGET IMPACT RATIONING CRITERION IN DRUG REIMBURSEMENT DECISIONS

    Nov 1, 2007, 00:00

  • POS11 FALL-RELATED HOSPITALIZATION AND FACILITY COSTS AMONG RESIDENTS RECEIVING LONG-TERM CARE

    Nov 1, 2007, 00:00

  • PDB6 DATABASE ASSESSMENT OFTHE EFFECTIVENESS OF BRAND VERSUS GENERIC ROSIGLITAZONE IN PATIENTS WITHTYPE 2 DIABETES MELLITUS

    Nov 1, 2007, 00:00

  • PUK18 INCREASING MARKET SHARE OF PRIVATE DIALYSIS CENTRES FROM HEALTH INSURANCE EXPENDITURES IN HUNGARY

    Nov 1, 2007, 00:00

  • PRS10 TREATMENT COSTS ASSOCIATED WITH COMMUNITY ACQUIRED PNEUMONIA BY COMMUNITY LEVEL OF ANTIMICROBIAL RESISTANCE

    Nov 1, 2007, 00:00

  • Meeting on the FDA Draft Guidance on Patient-Reported Outcomes

    Nov 1, 2007, 00:00

  • PGI18 THE QUALITY INDICATORS OF NURSING CARE AMONG PATIENTS WITH ACUTE PANCREATITIS IN HUNGARY

    Nov 1, 2007, 00:00

  • PEY3 RANIBIZUMAB (LUCENTIS®) IS A COST-EFFECTIVE TREATMENT OF AGE-RELATED MACULA DEGENERATION (AMD) IN THE GERMAN HEALTH CARE SYSTEM

    Nov 1, 2007, 00:00

  • PCN22 COST-EFFECTIVENESS OF SUNITINIBAS SECOND LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CANCER IN BELGIUM

    Nov 1, 2007, 00:00

  • PDB43 COMPARATIVE STUDY OF ANNUAL TREATMENT COSTS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN

    Nov 1, 2007, 00:00

  • POS4 ECONOMIC IMPACT OF FRENCH NEW GUIDELINES ON POST-MENOPAUSAL OSTEOPOROSIS DIAGNOSIS

    Nov 1, 2007, 00:00

  • PCV74 A COMPARATIVE PHARMACOECONOMIC ANALYSIS OF STATINS IN RUSSIA

    Nov 1, 2007, 00:00

  • PAR10 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF ANTI-TNF-A DRUGS IN PSORIATIC ARTHRITIS

    Nov 1, 2007, 00:00

  • PAA20 PHARMACOECONOMIC ANALYSIS OF A NEW CONCEPT FOR SYMBICORT USE IN BRONCHIAL ASTHMA PATIENTS

    Nov 1, 2007, 00:00

  • PCV21 COST-EFFECTIVENESS OF HYPERTENSION TREATMENT IN GREECE-THE ECON-APROS STUDY

    Nov 1, 2007, 00:00

  • PHM13 THE EFFECT OF RESTRICTING FERTILITY SERVICES IN GERMANY

    Nov 1, 2007, 00:00

  • PSK9 PRIOR AUTHORIZATION FOR TOPICAL PSORIASIS TREATMENTS- IS IT COST-BENEFICIAL FOR MANAGED CARE?

    Nov 1, 2007, 00:00

  • PR2 NON-PERSISTENT USE OF ORAL ANTIDIABETIC DRUGS LEADS TO 20% DECREASED CHANCE OF HBA1C GOAL-ATTAINMENT IN DAILY CLINICAL PRACTICE

    Nov 1, 2007, 00:00

  • PCV49 BUDGET IMPACT AND MEDICAL RESOURCES USED TO CONTROL BLEEDS IN PATIENTS HOSPITALIZED DUE TO ACUTE CORONARY SYNDROME (ACS)

    Nov 1, 2007, 00:00

  • PCV51 ESTIMATING THE IMPACT OF MANDATORY SWITCH FROM ATORVASTATINTO SIMVASTATIN IN NORWAY

    Nov 1, 2007, 00:00

  • ED4 THE RELATIVE COST EFFECTIVENESS OF SWITCHING TO INSULIN GLARGINE VERSUS NPH INSULIN IN INSULIN NAIVE AND NON INSULIN NAIVE TYPE 2 DIABETES PATIENTS USING UK REAL LIFE DATA

    Nov 1, 2007, 00:00

  • PMH57 EFFECTIVENESS OF A PSYCHOSOCIAL INTERVENTION PROGRAM FOR CAREGIVERS OF PATIENTS WITH ALZHEIMER'S DISEASE IN THE PREVENTION OR REDUCTION CAREGIVER BURDEN EDUCA STUDY

    Nov 1, 2007, 00:00

  • PCV22 COST EFFECTIVENESS ANALYSIS OF BOSENTAN FORTHE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN SOUTH KOREA

    Nov 1, 2007, 00:00

  • PAR32 INVESTIGATION OF RESPONSE SHIFT IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOINGTOTAL KNEE REPLACEMENT

    Nov 1, 2007, 00:00

  • PCN18 SUNITINIB VS. INTERFERON-ALPHA (IFN-ALPHA) IN FIRST-LINE METASTATIC RENAL CELL CARCINOMA (MRCC)- AN ECONOMIC EVALUATION

    Nov 1, 2007, 00:00

  • PMH41 A MULTI-CENTER STUDY OF ANTIPSYCHOTIC MEDICATION USE, TREATMENT DYNAMICS AND PATIENT SYMPTOMATOLOGY IN SPAIN. RESULTS FROM ANTIPSYCHOSISMONITOR INITIATIVE

    Nov 1, 2007, 00:00

  • PG19 PHARMACOECONOMIC ANALYSIS OF GERD TREATMENT AFTER OMEPRAZOLE FAILURE IN SPAIN

    Nov 1, 2007, 00:00

  • PGI19 INVESTIGATION OF OTC NSNSAID RATIONAL USE AND GASTROINTESTINAL DISEASES

    Nov 1, 2007, 00:00

  • PHM2 BUDGET IMPACT (Bl) OF PARENTERAL IRON TREATMENT OF IRON DEFICIENCY ANAEMIA (IDA) IN SWITZERLAND

    Nov 1, 2007, 00:00

  • PMH3 EFFECTIVENESS OF OLANZAPINE TREATMENT FOR SCHIZOPHRENIA- 12-MONTH RESULTS OF THE POST MARKETING SURVEILLANCE IN JAPAN

    Nov 1, 2007, 00:00

  • PIH13 FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF MAMMOGRAPHY SCREENING FOR BREAST CANCER

    Nov 1, 2007, 00:00

  • ES1 INCREMENTAL DIFFERENCES IN RESOURCE UTILIZATION AND COSTS OFTREATING PERSONS INFECTED WITH HIV IN A LOW SOCIOECONOMIC NEIGHBORHOOD

    Nov 1, 2007, 00:00

  • PUK4 IN THE UNITED KINGDOM, AN INCREASED UTILISATION OF PERITONEAL DIALYSIS THERAPY COULD LEAD TO AN INCREASE IN THE NUMBER OF PATIENTS BEING TREATED FOR RENAL REPLACEMENT THERAPY (RRT)

    Nov 1, 2007, 00:00

  • PHM21 UK COMMUNITY DERIVED UTILITIES USING TIME TRADE OFF FOR ORAL VERSUS SUBCUTANEOUS IRON CHELATION THERAPY FORTHETREATMENT OF CHRONIC IRON OVERLOAD

    Nov 1, 2007, 00:00

  • PCN16 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN

    Nov 1, 2007, 00:00

  • PMC12 DRUG ADMINISTRATION SERVICES- AN INFUSION STAGE MODEL IN A MULTI-SITE STUDY OF U.S. PHYSICIAN OFFICES

    Nov 1, 2007, 00:00

  • PMH2 A REVIEW OF PUBLISHED STUDIES ON THE BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) IN GERMANY

    Nov 1, 2007, 00:00

  • PMC18 THE ROLE OF CONCEPTUAL MODELS, ENDPOINT MODELS, AND CONCEPTUAL FRAMEWORKS WHEN MAKING TREATMENT BENEFIT CLAIMS TO THE FDA

    Nov 1, 2007, 00:00

  • PCV25 COST-EFFECTIVENESS OF PREHOSPITAL VERSUS INHOSPITAL THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2007, 00:00

  • PUK11 THE COST OF END STAGE RENAL DISEASE IN GREECE

    Nov 1, 2007, 00:00

  • PND16 OBJECTIVE COSTS AND PREVALENCE OF COMORBIDITIES DURING THE YEAR FOLLOWING DIAGNOSIS FOR PERSONS WITH AND WITHOUT INSOMNIA

    Nov 1, 2007, 00:00

  • PIH20 ASSOCIATION BETWEEN METABOLIC SYNDROME AND QUALITY OF LIFE IN MALE STAINLESS STEEL WORKERS

    Nov 1, 2007, 00:00

  • Prices for Innovative Pharmaceutical Products That Provide Health Gain- A Comparison Between Australia and the United States

    Nov 1, 2007, 00:00

  • PEY14 ASSESSMENT OF THE PERSISTENCE DEGREE IN PATIENTS WITH ANTIGLAUCOMA AGENTS AS FIRST LINE MONOTHERAPIES IN SPAIN

    Nov 1, 2007, 00:00

  • PCN76 COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2007, 00:00

  • PSK5 MANAGEMENT AND COST OF GENITAL WARTS IN ITALY

    Nov 1, 2007, 00:00

  • PCN35 ASSESSING THE IMPACT ON STAFF RESOURCES AND PATIENT WAITING TIME OF A SWITCH FROM IVTO ORAL CHEMOTHERAPY WITH VINORELBINE

    Nov 1, 2007, 00:00

  • POS7 COST-EFFECTIVENESS SIMULATION MODELING OF THE COMPLIANCE OF 5 MG ZOLEDRONIC ACID ONCE A YEAR VERSUS CURRENT TREATMENTS IN POST-MENOPAUSAL OSTEOPOROSIS

    Nov 1, 2007, 00:00

  • SU1 COST-EFFECTIVENESS OF CYCLOOXYGENASE-2 INHIBITOR PARECOXIB COMPARED TO OPIOIDS AFTER NONCARDIAC SURGERY INTHE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PCV28 COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES AFTER HIP FRACTURE REPAIR (HFR)

    Nov 1, 2007, 00:00

  • PG114 THE EPIDEMIOLOGY AND HEALTHMCARE RESOURCE USE IN PATIENTS WITH ULCERATIVE COLITIS-A POPULATION BASED UK STUDY

    Nov 1, 2007, 00:00

  • PMC11 DEALING WITH COMPETING CAUSES OF DEATH, ILLNESS AND COSTS-THE DISEASE ELIMINATION LIFE TABLE ANALYSIS (DELTA) MODEL

    Nov 1, 2007, 00:00

  • CV6 SIROLIMUS-ELUTING VERSUS BARE-METAL CORONARY STENTS- 18-MONTH CLINICAL AND ECONOMIC OUTCOMES OF A CONTROLLED STUDY FOR THE REDUCTION OF CORONARY RESTENOSIS

    Nov 1, 2007, 00:00

  • PCV44 COST-EFFECTIVENESS ANALYSIS OF THE USE OFVISIPAQUE COMPARED TO OMNIPAQUE IN THE UNITED KINGDOM (UK)

    Nov 1, 2007, 00:00

  • PCN38 COST-ANALYSIS OF XELOXVS. FOLFOX-4 ± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC) IN AN ITALIAN HOSPITAL SETTING

    Nov 1, 2007, 00:00

  • PCV67 MANAGEMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION (STEMI) ACCORDING TO GUIDELINES IN SPAIN

    Nov 1, 2007, 00:00

  • PDB67 PERSISTENCE PATTERNS WITH ORAL ANTI-HYPERGLYCEMIC DRUG TREATMENT IN NEWLYTREATED PATIENTS— A POPULATION-BASED STUDY

    Nov 1, 2007, 00:00

  • PMC13 NONLINEAR SMOOTHING TO ASSESS PROBABILITIES OF ANTIBIOTIC-RESISTANT INFECTIONS IN THE COMUNITAT VALENCIANA (SPAIN)

    Nov 1, 2007, 00:00

  • PDB19 THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH SITAGLIPTIN- AN ECONOMIC EVALUATION USING A VALIDATED ECONOMIC MODEL FROM ATHIRD PARTY PAYER PERSPECTIVE IN THE USA

    Nov 1, 2007, 00:00

  • PHM8 COST-MINIMIZATION ANALYIS OF DARBEPOETIN-α VERSUS EPOETIN-β IN DIALYSED PATIENTS- A LONG-TERM RETROSPECTIVE MONOCENTRIC ITALIAN STUDY

    Nov 1, 2007, 00:00

  • PHP40 PHARMACOECONOMIC EVALUATION IN THE IRISH HEALTH CARE SETTING

    Nov 1, 2007, 00:00

  • PCV37 COST-EFFECTIVENESS OF ATORVASTATIN, ROSUVASTATIN, AND SIMVASTATIN IN REDUCING LDL-CHOLESTEROL TO MEET THE EUROPEAN TARGET LEVEL—BAYESIAN META-ANALYSIS AND SIMULATION Peura P1. Martikainen JA1, Hallinen T1, Soini EJ1, Niskanen L2 Unive ...

    Nov 1, 2007, 00:00

  • PHP30 HEALTH OUTCOMES AMONG INDIVIDUALS WITH AND WITHOUT HEALTH INSURANCE IN THE UNITED KINGDOM- RESULTS OF A MATCHED SAMPLE ANALYSIS OF A RETROSPECTIVE DATABASE

    Nov 1, 2007, 00:00

  • PCV54 ATTAINMENT OF LDL CHOLESTEROL GOALS AMONG HIGH RISK PATIENTS WITH CARDIOVASCULAR DISEASE (CVD)- HOW LARGE WAS THE GAP BETWEEN EUROPE THE UNITED STATES (US) IN 2006?

    Nov 1, 2007, 00:00

  • PIN19 A COST-EFFECTIVENESS ANALYSIS OF A PROPHYLACTIC CERVICAL CANCERVACCINE IN GERMANY- RESULTS FROM A HEALTH ECONOMIC MODEL

    Nov 1, 2007, 00:00

  • ND2 MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN

    Nov 1, 2007, 00:00

  • PCV43 DIRECT COSTS ASSOCIATED WITH THE POTENTIAL COMPLICATIONS OF INCREASED CARDIOMETABOLIC RISK STATES

    Nov 1, 2007, 00:00

  • PDB76 TREATMENT SATISFACTION IS POSITIVELY ASSOCIATED WITH GLYCEMIC CONTROLAND NEGATIVELY ASSOCIATED WITH PATIENT REPORTED EXPERIENCE OF HYPOGLYCEMIC SYMPTOMS AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AG ...

    Nov 1, 2007, 00:00

  • PMH60 A PHARMACOECONOMIC COMPARISON OF ESCITALOPRAM AND DULOXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PCV26 COST-EFFECTIVENESS OF HIGH DOSE ATORVASTATIN COMPARED TO STANDARD DOSE PRAVASTATIN IN SECONDARY PREVENTION

    Nov 1, 2007, 00:00

  • PAA2 PREVALENCE OF UNCONTROLLED SEVERE PERSISTENT ASTHMA PATIENTS IN PNEUMOLOGY AND ALLERGY HOSPITAL UNITS IN SPAIN

    Nov 1, 2007, 00:00

  • PEY1 USE OF BAYESIAN NETWORKS TO SPECIFY NOCTURNAL IOP CONTROL BY PROSTAGLANDIN ANALOGUES ACCORDING TO SEVERAL THRESHOLDS FROM DAY-TIME MEASUREMENTS IN GLAUCOMA PATIENTS

    Nov 1, 2007, 00:00

  • PRS3 COSTS OF COPD IN SWEDEN ACCORDING TO DISEASE SEVERITY

    Nov 1, 2007, 00:00

  • PDB11 ASSOCIATION BETWEENTOPICAL CORTICOSTEROID USE AND DIABETES ONSET

    Nov 1, 2007, 00:00

  • PUK1 EFFECT OF LAUGHTER THERAPY ON STRESS AND HEALTH-RELATED QUALITY OF LIFE IN HEMODIALYSIS PATIENTS

    Nov 1, 2007, 00:00

  • PUK20 A COST EFFECTIVENESS ANALYSIS OF SOLIFENACIN COMPARED WITH EXTENDED-RELEASE TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER

    Nov 1, 2007, 00:00

  • PCN33 COST-MINIMIZATION ANALYSIS OF ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM VERSUS DAILY FILGRASTIM FORTHE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN BRAZIL

    Nov 1, 2007, 00:00

  • PG126 VALIDATED MEASURES OF HEALTH RELATED QUALITY OF LIFE AND PRODUCTIVITY IN A POPULATION OF PATIENTS REPORTING CHRONIC CONSTIPATION

    Nov 1, 2007, 00:00

  • PCN1 QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) OF FOTEMUSTINE COMPARED WITH DACARBAZINE IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA

    Nov 1, 2007, 00:00

  • Denouement- A Patient-Reported Observation

    Nov 1, 2007, 00:00

  • PUK6 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH TACROLIMUS (PROGRAF®) FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION

    Nov 1, 2007, 00:00

  • EC2 AN ECONOMIC EVALUATION OF DASATINIB AS A TREATMENT FOR CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA IN SCOTLAND

    Nov 1, 2007, 00:00

  • PCN28 ECONOMIC EVALUATION OF SWITCHING TO EXEMESTANE AT 2-3 YEARS VERSUS CONTINUING TAMOXIFEN AS ADJUVANT THERAPY IN EARLY BREAST CANCER- A FINNISH PERSPECTIVE

    Nov 1, 2007, 00:00

  • PIN20 COST EFFECTIVENESS ANALYSIS OF BRIVUDINE COMPARED WITH ACICLOVIR FORTHETREATMENT OF HERPES ZOSTER IN SPAIN

    Nov 1, 2007, 00:00

  • PCN69 PATIENT-REPORTED IMPAIRMENT OF EUROQOL HEALTH STATES AND PREFERENCE-WEIGHTED UTILITY IN ADVANCED RENAL CELL CARCINOMA IN A RECENT CLINICAL TRIAL

    Nov 1, 2007, 00:00

  • PUK2 COMPARING THE CLINICAL OUTCOMES FOLLOWING URINARY INCONTINENCE TREATMENT BY DIFFERENT TYPE OF SURGERY

    Nov 1, 2007, 00:00

  • PMH19 COMORBIDITYAND COSTS IN GENERALIZED ANXIETY DISORDERS AND FIBROMYALGIA SYNDROME IN THE PRIMARY CARE SETTING (PCS)- A COMPARISON OF TWO DISORDERS WITH HIGH DEMAND OF CARE

    Nov 1, 2007, 00:00

  • ND4 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN INTHE TREATMENT OF POST-HERPETIC NEURALGIA IN SCOTLAND

    Nov 1, 2007, 00:00

  • PHP36 PATIENT TRANSFER DECREASE AND HEALTH INSURANCE COSTS SAVINGS ASSOCIATED WITH TELEMEDICINE CONSULTATION. EXAMPLE OF THE TELEMEDICINE NETWORK OF “MIDI-PYRéNéES” (RTR)

    Nov 1, 2007, 00:00

  • PSU1 COST-EFFECTIVENESS OF STAPLED HAEMORRHOIDOPEXY (PPH) COMPARED WITH MILLIGAN-MORGAN TECHNIQUE MM IN PATIENTS IN WHOM SURGICAL INTERVENTION IS CONSIDERED APPROPRIATE FORTHETREATMENT OF PROLAPSED INTERNAL HAEMORRHOIDS IN UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PCV71 AN EVALUATION OF STATIN PERFORMANCES BIVARIATE AND TRIVARIATE SELECTION RULE APPROACH

    Nov 1, 2007, 00:00

  • PAA5 CLINICO-ECONOMICAL ANALYSIS OF USING BUDESONID/ FORMOTEROL INHALER FORTREATMENT OF BRONCHIAL ASTHMA

    Nov 1, 2007, 00:00

  • PDB16 GLYCEMIC CONTROL WITH INSULIN GLARGINE PLUS GLULISINE VERSUS PREMIX IN REALWORLD PRACTICES—A RANDOMIZED, PROSPECTIVE, OBSERVATIONAL STUDY

    Nov 1, 2007, 00:00

  • PR1 RECOMPUTING VALUES FOR EQ-5D IN ACCORDANCE WITH NICE APPRAISAL GUIDANCE

    Nov 1, 2007, 00:00

  • PCN71 CONJOINT ANALYSIS ATECHNIQUE TO DEVELOP A QUESTIONNAIRE OF TREATMENT PREFERENCES IN PATIENTS WITH LUNG CANCER

    Nov 1, 2007, 00:00

  • PAA16 A RETROSPECTIVE STUDY COMPARING TREATMENT PATTERNS, OUTCOMES, AND RESOURCE USE BETWEEN TWO FIXED COMBINATIONS OF INHALED CORTICOSTEROIDSAND LONG-ACTING B2-AGONIST (ICS/LABA) IN ASTHMATIC PATIENTS IN GERMANY

    Nov 1, 2007, 00:00

  • PMH10 REDUCTION IN SUICIDAL IDEATION, VIOLENT BEHAVIOUR, AND SELF INJURY AFTER TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)- 12 MONTH PRELIMINARY RESULTS FROM E-STAR PROJECT IN CZECH REPUBLIC AND SLOVAKIA

    Nov 1, 2007, 00:00

  • PIN18 COST-EFFECTIVENESS ANALYSIS OF OSELTAMIVIR FOR INFLUENZA IN JAPAN- MODELING IN THE VIRUS EMERGING RESISTANT TO THE DRUG

    Nov 1, 2007, 00:00

  • PIN22 A MULTINATIONAL PHARMACOECONOMIC EVALUATION OF DIRECT AND INDIRECT IMMUNITY CONFERRED BY THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV7)

    Nov 1, 2007, 00:00

  • PAR24 COST-UTILITY ANALYSIS OF RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS AFTER ANTI-TNF-ALFATHERAPY IN HUNGARY

    Nov 1, 2007, 00:00

  • PCV53 STATIN USE AMONG PATIENTS WITH CONFIRMED CORONARY ARTERY DISEASE (CAD) OR RELATED RISK FACTORS-A COMPARISON BETWEEN EUROPE THE UNITED STATES (US)

    Nov 1, 2007, 00:00

  • PDB78 COMPARISONS BETWEEN ITEQAND DTSQ IN A SAMPLE OF TYPE 2 DIABETES MELLITUS PATIENTS

    Nov 1, 2007, 00:00

  • PIN42 EVALUATING THE CLINICAL EFFECTS AND THE COST-EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCER VACCINATION WITHIN AN ORGANISED POPULATION-BASED SCREENING SETTING—CASE FINLAND

    Nov 1, 2007, 00:00

  • PIN24 THE COST-EFFECTIVENESS OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE (6, I 1,6, 18) IN NORWAY

    Nov 1, 2007, 00:00

  • PCV94 EFFECTS OF COMORBID CONDITIONS AMONG THE OVERWEIGHT/OBESE ON WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT

    Nov 1, 2007, 00:00

  • REVIEWER ACKNOWLEDGMENT

    Nov 1, 2007, 00:00

  • PRS15 EQ-5D UTILITIES ASSOCIATED WITH LEVELS OF COPD SEVERITY-A META-ANALYTIC APPROACH

    Nov 1, 2007, 00:00

  • PHP37 PHARMACOECONOMIC EDUCATION IN COLLEGES OF PHARMACY—2007

    Nov 1, 2007, 00:00

  • Abstracts Index

    Nov 1, 2007, 00:00

  • PCN13 ASSESSMENT OFTHE COST-EFFECTIVENESS IN AUSTRALIA OF CETUXIMAB IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CANCERS OFTHE HEAD AND NECK

    Nov 1, 2007, 00:00

  • PAA11 ECONOMIC EVALUATION OF SECOND-LINE THERAPIES IN ADULT PATIENTS WITH ASTHMA WHEN CONSIDERING COMPLIANCE—AN ANALYSIS FROM A SWEDISH HEALTH CARE PERSPECTIVE

    Nov 1, 2007, 00:00

  • PMH42 THE PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS ASSOCIATED WITH ATYPICAL ANTIPSYCHOTICS WITHIN ONTARIO DRUG BENEFIT CLAIMS

    Nov 1, 2007, 00:00

  • PDB13 THE COST OFTHE INEFFICIENCY IN DIABETES IN HEALTH PRIMARY CARE

    Nov 1, 2007, 00:00

  • PSK2 PSOBEST. EFFECTIVENESS AND SAFETY OF LONG-TERM SYSTEMIC PSORIASIS-THERAPY- PATIENT REGISTRY OF HEALTH SERVICES IN GERMANY

    Nov 1, 2007, 00:00

  • RS1 A RETROSPECTIVE, OBSERVATIONAL STUDY COMPARING OUTCOMES OF ASTHMATREATMENT WITH FIXED COMBINATIONS OF INHALED CORTICOSTEROID AND LONG-ACTING â2-AGONIST (ICS/LABA) IN REAL-LIFE PRACTICE

    Nov 1, 2007, 00:00

  • PMC34 BIBLIOGRAPHIC REVIEW OF DISCRETE EVENTS SIMULATION STUDIES IN HEALTH TECHNOLOGY EVALUATION

    Nov 1, 2007, 00:00

  • PMH9 TREATMENT RETENTION WITH RISPERIDONE LONG ACTING INJECTION (RLAI) IN EUROPEAN PATIENTS WITH SCHIZOPHRENIA- 12-MONTH INTERIM RESULTS FROM ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)

    Nov 1, 2007, 00:00

  • CV8 THE COST-EFFECTIVENESS (COST-UTILITY) OF EPROSARTAN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISEASE IN BELGIUM, GERMANY, SPAIN, UNITED KINGDOM, AND SWEDEN

    Nov 1, 2007, 00:00

  • PIH22 WILLINGNESS TO PAY OF YOUNG GREEK WOMEN FORTHE NEW ANTI-HUMAN PAPILOMA VIRUS VACCINE

    Nov 1, 2007, 00:00

  • PUK8 CMA OF MYCOPHENOLAN MOFETIL (MMF; CELLCEPT) OR TACROLIMUS (TAC; PROGRAF) IN KIDNEYTRANSPLANT IMMUNOSUPPRESSIVE THERAPY SCHEMES FROM PUBLIC PAYER'S PERSPECTIVE IN POLAND

    Nov 1, 2007, 00:00

  • PEY6 COST OF CATARACT SURGERY AFTER IMPLANTATION OF THREE INTRAOCULAR LENSES WITH SQUARE EDGES

    Nov 1, 2007, 00:00

  • PEY15 HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS IN FRANCE

    Nov 1, 2007, 00:00

  • RS4 ASTHMA COSTS AND UTILIZATION IN A MANAGED CARE ORGANIZATION

    Nov 1, 2007, 00:00

  • Real World Data

    Sep 1, 2007, 00:00

  • The Distribution of the Cost of Multiple Sclerosis in the UK- How Do Costs Vary by Illness Severity?

    Sep 1, 2007, 00:00

  • Comparison of Persistence Rates with Angiotensin-Converting Enzyme Inhibitors Used in Secondary and Primary Prevention of Cardiovascular Disease

    Sep 1, 2007, 00:00

  • Economic Evaluation of a Bayesian Model to Predict Late-Phase Success of New Chemical Entities

    Sep 1, 2007, 00:00

  • Time from Sexually Transmitted Infection Acquisition to Pelvic Inflammatory Disease Development- Influence on the Cost-Effectiveness of Different Screening Intervals

    Sep 1, 2007, 00:00

  • Principles of Good Practice for Budget Impact Analysis- Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis

    Sep 1, 2007, 00:00

  • Evidence for Coverage Decisions- The Need for a Reality Check

    Sep 1, 2007, 00:00

  • Item-Based versus Subscale-Based Mappings from the SF-36 to a Preference-Based Quality of Life Measure

    Sep 1, 2007, 00:00

  • Budget Impact Analyses Get Some Respect

    Sep 1, 2007, 00:00

  • Quality of Life Assessed with the Medical Outcomes Study Short Form 36-Item Health Survey of Patients on Renal Replacement Therapy- A Systematic Review and Meta-Analysis

    Sep 1, 2007, 00:00

  • Mapping FACT-P and EORTC QLQ-C30 to Patient Health Status Measured by EQ-5D in Metastatic Hormone-Refractory Prostate Cancer Patients

    Sep 1, 2007, 00:00

  • Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer

    Sep 1, 2007, 00:00

  • The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks

    Sep 1, 2007, 00:00

  • Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey

    Sep 1, 2007, 00:00

  • Using Real-World Data for Coverage and Payment Decisions- The ISPOR Real-World Data Task Force Report

    Sep 1, 2007, 00:00

  • Regarding Probabilistic Analysis and Computationally Expensive Models- Necessary and Required?

    Jul 1, 2007, 00:00

  • Development and Validation of a Scale to Measure Disease-Related Symptoms of Kidney Cancer

    Jul 1, 2007, 00:00

  • Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome- An Analysis of the TENOR Study

    Jul 1, 2007, 00:00

  • Literature Review of Questionnaires Assessing Vertigo and Dizziness, and Their Impact on Patients' Quality of Life

    Jul 1, 2007, 00:00

  • Validation of a Condition-Specific Measure for Women Having an Abnormal Screening Mammography

    Jul 1, 2007, 00:00

  • Assessing Differences in Utility Scores- A Comparison of Four Widely Used Preference-Based Instruments

    Jul 1, 2007, 00:00

  • Diabetes Cost Model of a Hospital in Thailand

    Jul 1, 2007, 00:00

  • The Cost-Effectiveness of Stem Cell Transplantations from Unrelated Donors in Adult Patients with Acute Leukemia

    Jul 1, 2007, 00:00

  • Estimation of Patient Preference-Based Utility Weights from the Functional Assessment of Cancer Therapy—General

    Jul 1, 2007, 00:00

  • The Methodological Quality of Economic Evaluations of Guideline Implementation into Clinical Practice- A Systematic Review of Empiric Studies

    Jul 1, 2007, 00:00

  • Decision Models Need to be “Fit for Purpose” for Decision-Making- Response to Caro et al.

    Jul 1, 2007, 00:00

  • The Impact of Gout on Work Absence and Productivity

    Jul 1, 2007, 00:00

  • PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS

    May 1, 2007, 00:00

  • PPN7 THE SPECTRUM OF HEALTH CARE COSTS ASSOCIATED WITH HERPES ZOSTER-ACUTE PAIN VS. POSTHERPETIC NEURALGIA

    May 1, 2007, 00:00

  • CASE 3 APPLICATION OF COST-EFFECTIVENESS ANALYSIS TO EVALUATE THE PROPOSED FORMULARY STATUS OF A NOVEL ANTIDIABETIC DRUG IN A U.S. COMMERCIAL HEALTH PLAN

    May 1, 2007, 00:00

  • PAA23 UNDERSTANDING PATIENT PERCEPTION OF THERAPY- DEVELOPMENT OF A WEEKLY DIARY TO DETERMINE WHETHER PATIENTS WITH ASTHMA CAN FEEL THEIR MAINTENANCE INHALER WORKING RIGHT AWAY

    May 1, 2007, 00:00

  • PSK5 QUALITY OF DERMATOLOGIC CARE DELIVERED BY PHYSICIAN ASSISTANTS-AN ANALYSIS OF CLOTRIMAZOLE/BETAMETHASONE PROPIONATE PRESCRIPTIONS

    May 1, 2007, 00:00

  • PRS11 PERCEPTIONS ABOUT BEHIND-THE-COUNTER AVAILABILITY OF PSEUDOEPHEDRINE

    May 1, 2007, 00:00

  • PPN14 OFF-LABEL OPIOID USE IN THE TREATMENT OF CHRONIC PAIN

    May 1, 2007, 00:00

  • PIN38 ASSESSING THE ASSOCIATION BETWEEN COMPLIANCE AND THERAPEUTIC FAILURE FOR ANTIRETROVIRAL DRUGS IN HIV POSITIVE PATIENTS

    May 1, 2007, 00:00

  • PND15 ECONOMIC CONSEQUENCES OF GENERIC SUBSTITUTION FOR ANTIEPILEPTIC MEDICATION-THE CASE OF LAMOTRIGINE

    May 1, 2007, 00:00

  • PCN21 DRUG UTILIZATION, COST CONSIDERATIONS AND TRANSFUSION PATTERNS FOR ERYTHROPOIETIC STIMULATING AGENTS IN A MANAGED CARE CANCER POPULATION

    May 1, 2007, 00:00

  • PCV17 COMPARING THE COST OF MICROSURGERY AND RADIOSURGERY FOR THE MANAGEMENT OF VESTIBULAR SCHWANNOMA

    May 1, 2007, 00:00

  • PPN19 VALIDATION OF INGUINAL PAIN QUESTIONNAIRE

    May 1, 2007, 00:00

  • PIN6 INITIATION OF ANTIVIRAL THERAPY AMONG CHRONIC HEPATITIS C PATIENTS ENROLLED IN MEDICAID

    May 1, 2007, 00:00

  • PCV26 COST-EFFECTIVENESS OF ROSUVASTATIN AND EZETIMIBE/SIMVASTATIN IN PATIENTS WITH DYSLIPIDEMIA IN MEXICO CITY

    May 1, 2007, 00:00

  • DB4 RETESTING OF HEMOGLOBIN A1C AFTER OUT-OF-RANGE RESULTS- CLINICAL PRACTICE VERSUS GUIDELINES

    May 1, 2007, 00:00

  • PCN43 ADHERENCE TO GUIDELINES FOR USE OF ERYTHROPOIESIS STIMULATING PROTEINS IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA-TRENDS FROM ELECTRONIC MEDICAL RECORDS

    May 1, 2007, 00:00

  • PPN5 COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINED ORAL TREATMENT WITH TRAMADOL/ACETAMINOPHEN (TRAMACET®) FOR THE MANAGEMENT OF LOWER BACK PAIN AT THE IMSS (MEXICAN INSTITUTE OF SOCIAL SECURITY)

    May 1, 2007, 00:00

  • PCV67 USING AN INTERNATIONAL DATABASE OF ACUTE CORONARY EVENTS TO ASSESS TODAY'S PRACTICE PATTERNS AND DESCRIBE TREATMENT STRATEGIES IN THE HOSPITAL SETTING

    May 1, 2007, 00:00

  • PAA1 RELATIONSHIP BETWEEN MEASURES OF ASTHMA CONTROL AND COMBINATION THERAPY TREATMENT REGIMENS IN SEVERE OR DIFFICULT-TO-TREAT ASTHMA

    May 1, 2007, 00:00

  • PCN52 COMPARISON OF IMPACT OF ELEVEN TYPES OF ADVANCED CANCER ON QUALITY OF LIFE

    May 1, 2007, 00:00

  • PDB2 GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS

    May 1, 2007, 00:00

  • PAA21 IS CURE WORSE THAN THE DISEASE?

    May 1, 2007, 00:00

  • PND21 PRODUCT ENHANCEMENTS DECREASE THE INCIDENCE OF INJECTION SITE REACTIONS AND PAIN RESULTING IN IMPROVED ADHERENCE TO THERAPY IN PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2007, 00:00

  • PCN16 THE RELATIONSHIP BETWEEN SHORT-TERM RESPONSE AND LONG-TERM OUTCOMES IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA

    May 1, 2007, 00:00

  • PHP39 QUALITY ASSESSMENT OF PHARMACOECONOMIC EVALUATIONS SUBMITTED FOR REIMBURSEMENT IN KOREA

    May 1, 2007, 00:00

  • PCV59 EFFECTIVENESS OF OUTPATIENT CLOPIDOGREL TREATMENT IN PREVENTING CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING STENTING FOR ACS- A RETROSPECTIVE CLAIMS DATABASE ANALYSIS

    May 1, 2007, 00:00

  • PCN4 BUDGET IMPACT ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

    May 1, 2007, 00:00

  • PAA19 THE EVOLUTION OF ASTHMA GUIDELINES FOR CHILDREN

    May 1, 2007, 00:00

  • PND17 PREVALENCE OF NON-ADHERENCE TO PARKINSON'S DISEASE MEDICATIONS AND ITS IMPACT ON SYMPTOM PROGRESSION IN A MEDICARE POPULATION

    May 1, 2007, 00:00

  • PMC26 EFFECT OF CHRONIC DISEASES ON HEALTH SERVICES UTILIZATION

    May 1, 2007, 00:00

  • PAR9 IMPACT OF PATIENT'S OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS

    May 1, 2007, 00:00

  • PCN6 A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH EXEMESTANE, ANASTROZOLE, LETROZOLE OR TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLYSTAGE BREAST CANCER IN MEXICO

    May 1, 2007, 00:00

  • PCN11 IS EARLY REPLACEMENT OF HORMONE THERAPY (HT) BY SEQUENTIAL CHEMOTHERAPY (CT) COST-EFFECTIVE IN HORMONE-RECEPTOR (HR) POSITIVE ADVANCED BREAST CANCER (ABC)?

    May 1, 2007, 00:00

  • PIN9 LENGTH OF STAY AND COSTS ASSOCIATED WITH SURGICAL SITE INFECTIONS IN COLON PROCEDURES IN A LARGE U.S. DATABASE

    May 1, 2007, 00:00

  • PHP11 THE VOLUNTARY INCENTIVE STRUCTURE OF PEDIATRIC EXCLUSIVITY AND ITS IMPACTS ON PHARMACEUTICAL INDUSTRY BEHAVIOR AND GENERIC DRUG ENTRIES

    May 1, 2007, 00:00

  • PCN10 COST-EFFECTIVENESS OF BREAST CANCER RISK ASSESSMENT IN PRIMARY CARE

    May 1, 2007, 00:00

  • PCV45 ARE MINORITIES MORE LIKELY TO BE INITIALLY DIAGNOSED OF HYPERTENSION DURING NON-OFFICE-BASED VISITS? EVIDENCE FROM MEDICAL EXPENDITURE PANEL SURVEY 1996-2003

    May 1, 2007, 00:00

  • PIH4 THE DIRECT AND INDIRECT COST BURDEN OF TREATED UTERINE FIBROIDS

    May 1, 2007, 00:00

  • PDB19 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN TYPE 1 DIABETES MELLITUS

    May 1, 2007, 00:00

  • PIN7 PREVALENCE OF CACHEXIA (WASTING SYNDROME) DIAGNOSIS AND TREATMENT AMONG PATIENTS WITH HIV/AIDS-A MEDICAL CLAIMS DATABASE ANALYSIS

    May 1, 2007, 00:00

  • PUK15 DRUG UTILIZATION AND COSTS OF ERYTHROPOIETIC AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE

    May 1, 2007, 00:00

  • PDB24 PRELIMINARY VALIDATION OF THE COGNITIVE DISTRESS, FATIGUE, HYPERGLYCEMIA AND HYPOGLYCEMIA SUBSCALES OF THE DIABETES SYMPTOM CHECKLIST REVISED (DCSR) FOR USE IN CLINICAL TRIALS INVOLVING PATIENTS WITH TYPE 1 OR TYPE 2 DIABETES

    May 1, 2007, 00:00

  • PHP14 POLYPHARMACY IN ELDERLY PATIENTS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY- SATISFACTION AND COSTS

    May 1, 2007, 00:00

  • PIN24 THE ECONOMIC IMPACT OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS AUREUS BACTEREMIA IN KOREA

    May 1, 2007, 00:00

  • PSM1 A LONG TERM COST–EFFECTIVENESS ANALYSIS MODEL FOR SMOKING CESSATION IN MEXICO

    May 1, 2007, 00:00

  • PDB8 COST-BENEFIT ANALYSIS OF INHALED INSULIN-A CANADIAN PERSPECTIVE

    May 1, 2007, 00:00

  • PIH2 E-PRESCRIBING REDUCES BEERS PRESCRIBING AMONG THE ELDERLY

    May 1, 2007, 00:00

  • PCV46 EFFECT OF MENTAL DISORDERS ON HEALTH CARE COST AMONG ELDERLY WITH DISEASES OF THE HEART

    May 1, 2007, 00:00

  • PIH9 PATIENT GENDER AND ASSOCIATED MEDICATION ADHERENCE IN AN OLDER POPULATION WITH CHRONIC DISEASES

    May 1, 2007, 00:00

  • PND18 DETERMINANTS OF EMERGENCY DEPARTMENT UTILIZATION FOR MIGRAINE CARE

    May 1, 2007, 00:00

  • PDB21 PRICE AND UTILIZATION OF ORAL ANTI-DIABETIC MEDICATIONS FROM 1991 TO 2005 IN U.S. MEDICAID PROGRAMS

    May 1, 2007, 00:00

  • PMC16 A COMPARISON OF CLINICAL TRIAL PARTICIPANTS TO THE GENERAL PATIENT POPULATION IN FRANCE, GERMANY AND UK

    May 1, 2007, 00:00

  • PCV39 TRENDS IN THE OFF-LABEL PRESCRIBING OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A (HMG-COA) REDUCTASE INHIBITORS IN THE UNITED STATES- 1998 TO 2004

    May 1, 2007, 00:00

  • MH4 MEASURING THE INFLUENCE OF MANAGED CARE ON ANTIDEPRESSANT UTILIZATION BY CHILDREN AND ADOLESCENTS WITH DEPRESSION

    May 1, 2007, 00:00

  • PDB4 THE EFFECTIVENESS OF DANCE THERAPY AMONG ADULT PATIENTS WITH DIABETES MELLITUS TYPE II

    May 1, 2007, 00:00

  • PDB28 IMPACT OF INITIATING OR CONVERTING TO TREATMENT WITH AN INSULIN ASPART ANALOG PEN ON MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS ON VIAL/SYRINGE INSULIN

    May 1, 2007, 00:00

  • PPN18 SYSTEMATIC OVERVIEW OF THE PSYCHOMETRIC PROPERTIES OF THE BRIEF PAIN INVENTORY IN MALIGNANT AND NON-MALIGNANT PAIN

    May 1, 2007, 00:00

  • PDB10 A PHARMACOECONOMIC EVALUATION FOR THE TREATMENT OF MEXICAN PATIENTS WITH DIABETES TYPE 2

    May 1, 2007, 00:00

  • PMC13 JOINT DETERMINATION OF PRICES, RESEARCH EXPENDITURE AND MARKETING EXPENDITURE BY PHARMACEUTICAL FIRMS-A THEORETICAL MODEL OF PROFIT-MAXIMIZING BEHAVIOR

    May 1, 2007, 00:00

  • PEY4 INCREMENTAL COSTS ASSOCIATED WITH ANTIBIOTICS PRESCRIBED FOR ACUTE OTITIS MEDIA

    May 1, 2007, 00:00

  • PIN20 PHARMACOECONOMIC ANALYSIS OF SEVERE COMMUNITYACQUIRED PNEUMONIA TREATMENT

    May 1, 2007, 00:00

  • PAR2 COST OF PAIN THERAPY FOR OSTEOARTHRITIS IN A PRIVATELY INSURED POPULATION IN THE UNITED STATES

    May 1, 2007, 00:00

  • PMC25 A MEDIAN MODEL OF US EQ-5D HEALTH STATE PREFERENCES

    May 1, 2007, 00:00

  • PAA13 CATEGORIES AND TRANSITION PATTERNS OF GUIDELINE INFORMED CONTROL IN SEVERE OR DIFFICULT-TO-TREAT ASTHMA

    May 1, 2007, 00:00

  • NE4 COST-UTILITY ANALYSIS EVALUATING LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN FOR POSTHERPETIC NEURALGIA IN SCOTLAND

    May 1, 2007, 00:00

  • PMC6 A COST-EFFECTIVENESS STUDY OF TRANSPORTING PERSONS WITHOUT MEDICAL NEEDS BY AMBULANCE. A PROSPECTIVE STUDY OF AMBULANCE SERVICE IN SWEDEN

    May 1, 2007, 00:00

  • PMC31 PROPOSAL FOR A METHODOLOGICAL CHANGE OF PRACTISE- SEPARATING THE PROCESS OF ESTIMATING CLINICAL EFFECTIVENESS FROM ECONOMIC EVALUATIONS

    May 1, 2007, 00:00

  • PDB13 COPAYMENT LEVEL AND MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS MANAGED WITH INSULIN ASPART PEN THERAPY

    May 1, 2007, 00:00

  • MC2 COMPARISON OF TRADITIONAL MULTIVARIABLE LOGISTIC REGRESSION AND PROPENSITY SCORE APPROACHES FOR CONTROLLING FOR TREATMENT SELECTION BIAS USING MONTE CARLO SIMULATION

    May 1, 2007, 00:00

  • PIN10 ANALYSIS OF INCIDENCE, RESOURCE USE AND COSTS OF SEVERE SEPSIS IN BRAZIL AND THE ECONOMIC IMPACT OF DROTRECOGIN-ALFA ACTIVATED

    May 1, 2007, 00:00

  • PIH7 CHARACTERISTICS ASSOCIATED WITH BENZODIAZEPINE USAGE IN ELDERLY OUTPATIENTS IN TAIWAN

    May 1, 2007, 00:00

  • PGI7 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH CONSTIPATION (C-ONLY) AND CO-OCCURRING IRRITABLE BOWEL SYNDROME AND CONSTIPATION (IBS+C) COMPARED TO MIGRAINE IN A LARGE MANAGED CARE POPULATION

    May 1, 2007, 00:00
  • «
  • 151
  • 152
  • 153
  • 154 (current)
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • »